Related Experiment Video
Updated: Jan 13, 2026
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Application of nanoparticles in the therapeutic management of endometrial cancer
Da Ke1, Wenzhe Li1, Qian Chen2
1Department of Endocrinology, The First Affiliated Hospital of Yangtze University, Jingzhou First People's Hospital, Jingzhou, Hubei, China.
Abstract:
The management of endometrial cancer (EC) remains challenging due to metastatic risk, therapeutic resistance, and the modest durability of standard regimens. Nanotechnology offers a promising avenue to overcome these limitations by enhancing tumor-selective drug delivery, enabling controlled release, and facilitating multimodal approaches that integrate therapy and imaging. This review systematically summarizes recent advances in nanoparticle applications for EC, focusing on strategies that target key molecular drivers, such as TP53, PI3K/PTEN, and immune checkpoints, and evaluates localized administration routes such as vaginal delivery. Preclinical studies, including the demonstration of JX06-loaded nanoparticles combined with metformin achieving approximately 86% viability inhibition in patient-derived EC cells, underscore the potential of nanoformulations to improve intracellular delivery and therapeutic efficacy. However, current research remains constrained by its reliance on limited cell lines and immunodeficient animal models. Clinically validated active targeting efficacy has yet to be established in EC, and translational progress is further hindered by the inconsistent enhanced permeability and retention (EPR) effect, accelerated blood clearance upon repeated dosing, as well as manufacturing and regulatory challenges. Through rational design of the targeting functionality and controlled-release properties of nanocarriers, combined with EC-specific disease models and biomarker-guided clinical trials, nanotechnology holds promise for overcoming existing therapeutic limitations. With continued advancement in translational research, nanotherapeutic platforms are expected to synergize with surgery, radiotherapy, and systemic treatments, thereby paving the way for more durable and personalized therapeutic options for EC patients. This review systematically summarizes the latest research progress in nanotechnology for EC treatment, providing a solid theoretical foundation and clear research directions to accelerate the clinical translation of nanomedicine in this field.
Insights
Nanotechnology offers new hope for endometrial cancer (EC) treatment by improving targeted drug delivery and overcoming resistance. Further research is needed to translate these promising nanoformulations into effective clinical therapies for EC patients.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Endometrial cancer (EC) management is difficult due to metastasis, resistance, and limited treatment durability.
- Nanotechnology can enhance tumor-specific drug delivery, controlled release, and integrated therapy/imaging for EC.
- Targeting molecular drivers (TP53, PI3K/PTEN, immune checkpoints) and localized delivery are key strategies.
Purpose of the Study:
- To systematically review recent advances in nanoparticle applications for endometrial cancer (EC).
- To evaluate strategies targeting molecular drivers and localized administration routes.
- To identify challenges and future directions for nanomedicine in EC treatment.
Main Methods:
- Systematic review of recent research on nanoparticle applications in EC.
- Focus on strategies targeting molecular drivers and localized delivery methods.
- Analysis of preclinical data and translational challenges.
Main Results:
- Nanoparticles show potential in preclinical EC models, e.g., JX06-loaded nanoparticles with metformin inhibited viability by ~86%.
- Nanoformulations can improve intracellular delivery and therapeutic efficacy.
- Current research relies on limited models, and clinical validation of active targeting and EPR effect is lacking.
Conclusions:
- Nanotechnology holds promise for overcoming EC therapeutic limitations through rational nanocarrier design and controlled release.
- Advancements in EC-specific models and biomarker-guided trials are crucial for clinical translation.
- Nanotherapeutics are expected to synergize with existing treatments for durable, personalized EC therapy.
